An FDA advisory panel is considering a new type of influenza vaccine that uses mRNA technology, drawing on the same platform used for COVID-19 vaccines. Health advisers are reviewing the vaccine’s evidence and whether it meets safety and effectiveness standards for preventing flu. The discussion is taking place at a panel meeting referenced by multiple outlets, which describe the product as a first-of-its-kind flu vaccine employing mRNA. The deliberations focus on the data submitted for the candidate vaccine, including how it is expected to work and what trial results indicate about protection against influenza. The review comes as regulators assess how mRNA approaches could be applied to seasonal flu vaccination. Final regulatory decisions, including whether the vaccine is approved for use, depend on the outcome of the panel’s review and subsequent FDA action.